“…Both BQR and LFM are immunosuppressive agents, although whether the mechanism of action is solely via pyrimidine inhibition remains controversial and unclear (44)(45)(46). The efficacy of BQR against graft rejection has been investigated extensively in preclinical models (47)(48)(49), and LFM has been proposed as an off-label immunosuppressive therapy in bone marrow (11) and renal (50) transplantation. In addition, DHODH inhibitors have been explored as treatments of other diseases, including malaria, autoimmune and inflammatory dis- eases, cancer, rheumatoid arthritis, and psoriasis (51)(52)(53)(54)(55).…”